Back to Journals » Clinical Epidemiology » Volume 12

Risk of Anemia in Patients with Newly Identified Chronic Kidney Disease – A Population-Based Cohort Study

Authors Vestergaard SV, Heide-Jørgensen U, van Haalen H, James G, Hedman K, Birn H, Thomsen RW, Christiansen CF

Received 23 April 2020

Accepted for publication 2 August 2020

Published 11 September 2020 Volume 2020:12 Pages 953—962

DOI https://doi.org/10.2147/CLEP.S259648

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Dr Eyal Cohen


Søren Viborg Vestergaard,1 Uffe Heide-Jørgensen,1 Heleen van Haalen,2 Glen James,3 Katarina Hedman,4 Henrik Birn,5,6 Reimar Wernich Thomsen,1 Christian Fynbo Christiansen1

1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2Health Economics & Payer Evidence, AstraZeneca, Gothenburg, Sweden; 3Epidemiology, AstraZeneca, Cambridge, UK; 4Biometrics, AstraZeneca, Gothenburg, Sweden; 5Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark; 6Department of Biomedicine, Aarhus University, Aarhus, Denmark

Correspondence: Søren Viborg Vestergaard
Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, Aarhus N 8200, Denmark
Tel +45 87168514
Email sovi@clin.au.dk

Purpose: Anemia is prevalent in patients with chronic kidney disease (CKD), but the longitudinal risk of anemia in patients with newly identified CKD is unknown. We therefore examined the risks of experiencing anemia in persons with newly identified CKD.
Patients and Methods: This cohort study included adult patients with newly identified CKD stages 3– 5 defined by an estimated glomerular filtration rate (eGFR) level < 60 mL/min/1.73m2 (at least two measurements ≥ 90 days apart) ascertained from a population-based registry with complete laboratory test results in Northern Denmark (population ∼ 2.2 million) during 2009– 2016. We calculated 1) cumulative incidence (risk) of anemia [hemoglobin < 12/< 13 g/dl in women/men] by CKD stage, and 2) adjusted hazard ratios (HRs) of anemia using Cox regression analyses.
Results: We identified 55,940 distinct individuals with newly identified CKD stages 3– 5 and no prevalent anemia [n=41,958 patients in stage 3a, n=17,875 in stage 3b, n=5182 in stage 4, and n=931 in stage 5]. After one year, 42.3% (95%-confidence interval [CI]: 41.9– 42.7) of patients with CKD stages 3– 5 had newly measured anemia, increasing to 67.7% (95%-CI: 67.2– 68.2) after five years. The absolute and relative anemia risk increased markedly with higher CKD stages. The adjusted HR of any anemia was 5.42 (95%-CI: 5.09– 5.77) in patients with CKD stage 5 compared to patients with CKD stage 3a.
Conclusion: Patients with newly identified CKD stages 3– 5 have a substantial risk of anemia, increasing with higher CKD stages. This study underlines that clinical awareness of anemia risk is important in patients with newly identified or progressed CKD.

Keywords: anemia, chronic kidney disease, CKD, epidemiology, cohort study

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]